KZR
Kezar Life Sciences, Inc.NASDAQHealthcare$7.40+0.00%ClosedMarket Cap: $54.2M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.77
P/S
0.00
EV/EBITDA
0.32
DCF Value
$9.69
FCF Yield
-95.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-64.4%
ROA
-73.1%
ROIC
-72.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-8.3M | $-14.5M | $-1.99 | — |
| FY 2025 | $0.00 | -Infinity% | $-52.3M | $-56.0M | $-7.66 | — |
| Q3 2025 | $0.00 | -Infinity% | $-11.7M | $-11.2M | $-1.53 | — |
| Q2 2025 | $0.00 | NaN% | $-14.6M | $-13.7M | $-1.87 | — |
| Q1 2025 | $0.00 | NaN% | $-17.6M | $-16.6M | $-2.27 | — |
| Q4 2024 | $0.00 | NaN% | $-21.6M | $-20.2M | $-2.77 | — |
| FY 2024 | $0.00 | NaN% | $-90.6M | $-83.7M | $-1.15 | — |
| Q3 2024 | $0.00 | NaN% | $-21.9M | $-20.3M | $-0.28 | — |
| Q2 2024 | $0.00 | NaN% | $-23.4M | $-21.5M | $-0.30 | — |
| Q1 2024 | $0.00 | -Infinity% | $-23.7M | $-21.7M | $-0.30 | — |
| Q4 2023 | $0.00 | -Infinity% | $-28.4M | $-32.3M | $-0.44 | — |
| FY 2023 | $7.0M | 100.0% | $-111.4M | $-101.9M | $-1.40 | — |